ATE325872T1 - Verfahren und zusammensetzungen zur behandlung von krebs - Google Patents

Verfahren und zusammensetzungen zur behandlung von krebs

Info

Publication number
ATE325872T1
ATE325872T1 AT96942100T AT96942100T ATE325872T1 AT E325872 T1 ATE325872 T1 AT E325872T1 AT 96942100 T AT96942100 T AT 96942100T AT 96942100 T AT96942100 T AT 96942100T AT E325872 T1 ATE325872 T1 AT E325872T1
Authority
AT
Austria
Prior art keywords
methods
compositions
treating cancer
treatment
vector
Prior art date
Application number
AT96942100T
Other languages
English (en)
Inventor
Gary L Clayman
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE325872T1 publication Critical patent/ATE325872T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96942100T 1995-11-30 1996-11-27 Verfahren und zusammensetzungen zur behandlung von krebs ATE325872T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US781095P 1995-11-30 1995-11-30

Publications (1)

Publication Number Publication Date
ATE325872T1 true ATE325872T1 (de) 2006-06-15

Family

ID=21728237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942100T ATE325872T1 (de) 1995-11-30 1996-11-27 Verfahren und zusammensetzungen zur behandlung von krebs

Country Status (19)

Country Link
US (3) US20020077313A1 (de)
EP (1) EP0863984B1 (de)
JP (1) JP2000501394A (de)
KR (1) KR19990071795A (de)
CN (2) CN101028523A (de)
AT (1) ATE325872T1 (de)
AU (1) AU722042B2 (de)
CA (1) CA2238829A1 (de)
CZ (1) CZ296810B6 (de)
DE (1) DE69636120T2 (de)
DK (1) DK0863984T3 (de)
ES (1) ES2264145T3 (de)
HU (1) HUP9902068A3 (de)
NO (1) NO982481L (de)
NZ (1) NZ324168A (de)
PL (1) PL186018B1 (de)
RU (1) RU2174409C2 (de)
SK (1) SK70598A3 (de)
WO (1) WO1997020047A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
RU2219553C2 (ru) * 2001-10-18 2003-12-20 Ростовский научно-исследовательский онкологический институт Способ определения эффективности аутогемохимиотерапии рака ректосигмоидного отдела прямой кишки и сигмовидной кишки, а также аутогемохимиотерапии в сочетании с свч-гипертермией рака прямой кишки
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
CA2496918A1 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
US20050037986A1 (en) * 2002-12-27 2005-02-17 Yoo George H. p53 treatment of papillomavirus and carcinogen-transformed cells in hyperplastic lesions
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
TR200503561T2 (tr) * 2003-03-06 2006-09-21 Peng Zhaohui Bir virüs vektörü ve bir insan tümör süpresor geni tarafından yapılandırılan bir yeniden birleştirici-harmanlayıcı (rekombinant) ve bunun kullanımı
RU2234099C1 (ru) * 2003-03-18 2004-08-10 Российская медицинская академия последипломного образования Способ дифференциальной диагностики стадий канцерогенеза
RU2242936C1 (ru) * 2003-04-21 2004-12-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака легкого
KR20120084333A (ko) * 2004-02-23 2012-07-27 노파르티스 포르슝스티프퉁 쯔바이크니덜라쑹 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 Ｍｔｏｒ 억제제와 세포독성제의 복합 치료에 대한 바이오마커로서의 ｐ53 야생형
US20080293652A1 (en) * 2004-02-24 2008-11-27 Introgen Therapeutics, Inc. Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
RU2245551C1 (ru) * 2004-04-23 2005-01-27 Белохвостов Александр Сергеевич Способ диагностики онкологических заболеваний
RU2263494C1 (ru) * 2004-06-08 2005-11-10 ГУ НИИ глазных болезней РАМН Способ моделирования меланомы роговицы
EP1799226A1 (de) * 2004-08-31 2007-06-27 Novartis AG Verwendung von midostaurin zur behandlung von gastrointestinalem stromatumor
EP1679065A1 (de) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
UA94899C2 (ru) * 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
MX2007009012A (es) * 2005-01-27 2007-09-14 Novartis Vaccines & Diagnostic Metodos para tratar carcinoma de celulas renales.
EP1880235A4 (de) * 2005-05-06 2008-05-28 Orthosoft Inc Hf-system zum verfolgen von gegenständen
WO2007090125A2 (en) * 2006-01-30 2007-08-09 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
RU2371202C2 (ru) * 2007-07-30 2009-10-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ радионуклидной диагностики рака молочной железы
CN106841616B (zh) 2008-01-25 2019-06-04 茂体外尔公司 P53生物标记物
US8314068B2 (en) * 2008-04-14 2012-11-20 University Hospitals Of Cleveland P2X7 inhibition of epithelial cancers and papillomas
US20120052003A9 (en) * 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
RU2384845C1 (ru) * 2008-12-18 2010-03-20 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов ФМБА Способ диагностики онкологических заболеваний
AU2010209938A1 (en) * 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
RU2395234C1 (ru) * 2009-07-24 2010-07-27 Учреждение Российской Академии Наук Институт Молекулярной Биологии Им. В.А. Энгельгардта Ран (Имб Ран) ОПРЕДЕЛЕНИЕ СНИЖЕНИЯ УРОВНЯ мРНК ГЕНА ZG16 КАК СПОСОБ ДИАГНОСТИКИ РАКА ТОЛСТОЙ КИШКИ И НАБОР ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
PL2635299T3 (pl) 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
US9175312B2 (en) * 2011-12-08 2015-11-03 Virovek Incorporation Vectors harboring toxic genes, methods and uses therefor
US9182861B2 (en) 2012-01-12 2015-11-10 Synaptics Incoporated Single layer capacitive imaging sensors
NZ627528A (en) * 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
PL2830662T3 (pl) 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
JP2016515508A (ja) 2013-03-15 2016-05-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 融合タンパク質及びその方法
SG11201507964TA (en) * 2013-03-27 2015-10-29 Ge Healthcare As Method and reagent for preparing a diagnostic composition
EP3010519B1 (de) * 2013-06-18 2021-04-07 Dnatrix Inc. Onkolytischen adenoviren zur verwendung in der behandlung von hirnkrebs
US9552089B2 (en) 2013-08-07 2017-01-24 Synaptics Incorporated Capacitive sensing using a matrix electrode pattern
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
CN104357408A (zh) * 2014-03-13 2015-02-18 哈尔滨博翱生物医药技术开发有限公司 一种重组新城疫病毒及其应用
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
RS58244B1 (sr) 2014-09-30 2019-03-29 Diadem S R L Antitelo koje vezuje linearni epitop humanog p53 i njegove dijagnostičke primene
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
EP3925979A3 (de) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusionsproteine und verfahren dafür
US10990148B2 (en) 2015-01-05 2021-04-27 Synaptics Incorporated Central receiver for performing capacitive sensing
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
CN205028263U (zh) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 一种电容传感器
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (zh) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 单层传感器图案和感测方法
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
RU2760993C1 (ru) * 2021-02-15 2021-12-02 Сергей Александрович Никитин Способ рентгеновской терапии рака легких

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US5055400A (en) * 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US5017524A (en) * 1989-02-13 1991-05-21 Iscar Ltd. Ceramic cutting tool
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US6800617B1 (en) * 1989-03-29 2004-10-05 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US6677312B1 (en) * 1989-03-29 2004-01-13 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien

Also Published As

Publication number Publication date
NO982481L (no) 1998-07-29
US20020077313A1 (en) 2002-06-20
CZ165798A3 (cs) 1998-12-16
DE69636120D1 (de) 2006-06-14
KR19990071795A (ko) 1999-09-27
JP2000501394A (ja) 2000-02-08
PL327009A1 (en) 1998-11-09
EP0863984A1 (de) 1998-09-16
AU1126397A (en) 1997-06-19
HUP9902068A3 (en) 2001-02-28
DE69636120T2 (de) 2006-11-30
NO982481D0 (no) 1998-05-29
CA2238829A1 (en) 1997-06-05
PL186018B1 (pl) 2003-09-30
EP0863984B1 (de) 2006-05-10
WO1997020047A1 (en) 1997-06-05
CN101028523A (zh) 2007-09-05
CN1308450C (zh) 2007-04-04
NZ324168A (en) 2004-11-26
HUP9902068A2 (hu) 1999-10-28
US20060035857A1 (en) 2006-02-16
RU2174409C2 (ru) 2001-10-10
ES2264145T3 (es) 2006-12-16
US20030166603A1 (en) 2003-09-04
SK70598A3 (en) 1999-04-13
AU722042B2 (en) 2000-07-20
CN1207771A (zh) 1999-02-10
DK0863984T3 (da) 2006-08-28
CZ296810B6 (cs) 2006-06-14

Similar Documents

Publication Publication Date Title
ATE325872T1 (de) Verfahren und zusammensetzungen zur behandlung von krebs
BR9610522A (pt) Composição para lavagem do corpo e processo para o tratamento da pele
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69737793D1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69936444D1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DK0623134T3 (da) Metalkomplekser af vandopløselige texaphyriner
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ID25622A (id) Proses untuk memproduksi formulasi arsenat trioksida dan metoda untuk mengobati kanker dengan menggunakan arsenat trioksida atau melarsoprol
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
MX9502240A (es) Pigmento opticamente variable, composiciones que lo contienen y proceso para su produccion.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
MY164077A (en) Compositions and uses of et743 for treating cancer
AU5690196A (en) 1h-pyrrol-1-yl and 1h-indol-1-yl aryl sulphones, processes f or their preparation and use for the therapy of hiv-1 infect ions
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
BR9610835A (pt) Composição cosmética ou dermatológica e processo não terapêutico de tratamento de matérias queratínicas
BR9806171A (pt) Composição cosmética e/ou dermatológica e pronta para uso, processo para tintura e para tratamento das fibras de queratina e dispositivo ou 'kit' de tintura de multi-compartimento
ATE257708T1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
ATE232390T1 (de) Osmotisches nicht-fermentiertes laxans zur behandlung und vorbeugung von kolorektalem krebs
BE893738A (fr) Compositions cosmetiques pour le traitement des cheveux et de la peau contenant des polymeres essentiellement constitues de motifs repetitifs du type beta-alanine
FI924475A7 (fi) Trinitrobentseenien tai karmiinihapon käyttö syövän ja virusperäisten sairauksien hoidossa
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
EP0907720A4 (de) Kombinierte radiotherapie und immuntherapie zur behandlung von krebs
DE60008077D1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0863984

Country of ref document: EP